Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. - Wikidata - awgldk - TriplyDB

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q52905253

about

Chemotherapy-induced peripheral neurotoxicity: a critical analysis Vincristine-induced peripheral neuropathy in pediatric cancer patients Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials Persistent mobility disability after neurotoxic chemotherapy Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial Longitudinal assessment of oxaliplatin-induced neuropathy.Platinum-induced neurotoxicity and preventive strategies: past, present, and future Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.Bortezomib-induced peripheral neurotoxicity: an update.The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.Patient-reported neuropathic pain in adolescent and young adult cancer patients.Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia.Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers.Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study.Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy.Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy.Impact of oxaliplatin-induced neuropathy: a patient perspective.

P2860

Q27010318-E704470C-E4B5-4004-9750-3D6B715D76F8 Q28078232-3140C222-5062-4575-8464-210660F37A92 Q30818191-0F818470-58F7-4768-930D-77829BCD19FA Q33632270-D2120D6F-36C4-4742-8C64-73479D2C89BA Q34180965-5ECFE7BA-B964-455E-9149-44229276999A Q34259315-A757081D-8978-40A4-89A2-16179AF40A00 Q34336573-58848D0A-EEAD-4A99-A1BB-EE0D2B481F3D Q35210263-C0E2498B-C09A-49BE-A2F6-A34A300E7307 Q35345734-48EB95C1-FCFF-4499-AC55-F063AED2A579 Q35584874-CEEE7063-9A0B-4A64-BE83-772C0DFAD070 Q35642335-E7B4DE32-6B0F-470F-AE21-164E2629C566 Q35722135-5C4D1400-19FA-4E66-9224-C482E2E83E77 Q36176588-FD24EF4E-407C-4A85-8308-C72D41872EA7 Q36551631-B88678C5-34D5-4A93-9036-E5C0808B4186 Q37375212-B4126BD8-9CDA-48BF-8957-FA95BBB8D4D9 Q37632970-35F2BF5A-F992-4FD0-AA98-6999E45EB02D Q37760210-2624F87C-D658-4A17-ADF8-B0EA87BAD5C7 Q37959375-9CA845B2-27EE-4B0D-AF56-F3E9DD3AD7DB Q38204277-DB7017BE-72A0-49AA-AA1C-46D8905DC58F Q38222174-F3E537A6-219F-4268-9C47-E000B1F78016 Q38224422-32A09FBC-9736-4EEF-9308-18B0CE473FCF Q38234733-ED219BE4-BE9A-405A-8FCF-E1F89836D28F Q38700984-AFF365D5-733B-4E8B-B3A5-6B823FE39F4E Q38716340-B4E13145-73D1-4C03-BA7A-BA11220DB0BF Q38722948-E83451DB-141B-4ACD-B012-9D8AE9581F66 Q38747276-4EB9B45C-8979-411A-8361-6EA709CE5CC5 Q39146230-066E8184-CF67-436E-85F9-5832694A3AAB Q40358186-D0925FA3-A132-47CD-AA26-EC0D45789AFB Q41512562-FC502901-1A25-4705-A1D8-501039BF2C60 Q41705410-C5339CCA-5A66-4FC6-9CAE-10A3D821FF97 Q45350320-B38A7806-5233-4A50-BD33-56E78E1D2462 Q46207519-CC1E3DF3-BDD6-4367-BED4-CCAF5E457CD5 Q47892453-8C640628-4388-4675-97EA-337D9E59D00D Q47979421-E66ABFCA-3B5D-4446-A4CA-F237953FC4D4 Q48211665-062F7CC6-6F0E-430D-B623-237653CCE831 Q48443184-BEF7CABA-2EFC-457F-951B-DBDB895A9E9A Q49520475-EBD35828-CF88-465E-99F9-91BE0F1B66E5 Q50002199-F7DB769D-4149-41C2-B212-97FB04BACF7C Q50477556-17D26214-3634-4AFD-B27F-A70732D3EC44 Q50956973-A37FF65A-A6C6-474D-BD9B-6274F63D0245

P2860

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q52905253

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh-hant

name

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@en

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@nl

type

label

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@en

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@nl

prefLabel

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@en

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@nl

P1433

Q52905253-273429A8-ACAE-45E0-9ED9-D4A5ACC3D588

P1476

Q52905253-35BD8F3E-881B-4984-BA24-F044978B83AC

P2093

Q52905253-3B1D5928-FB02-4B24-A403-5707B7EC55F2

Q52905253-A32929BC-AD22-411F-9D48-9DB94439B136

Q52905253-C1F0934D-FBD4-4EAE-A58B-981B3C83DB1F

Q52905253-E436D318-9E73-4E07-8C53-849845FCF0FF

Q52905253-ED1AFD2B-1A1F-49D0-BF7C-8AFCDFEF92EC

Q52905253-FE6A4A26-5750-45C2-AC72-75A22A62C1E7

P304

Q52905253-DE22ADD8-69D4-49DB-9DFD-81D9D3709699

P31

Q52905253-5A25F132-7A3D-49D1-BA20-5997616E659F

P356

Q52905253-E89AB37B-DE11-4ECA-8B7C-5E3496C363D4

P433

Q52905253-82F13630-26AC-426A-A044-C0A50712DCBB

P478

Q52905253-C6867F74-6514-4EA2-A766-989FA16F95EA

P577

Q52905253-FB63B757-92CB-44F6-B5AC-AA51E508C1A0

P698

Q52905253-80A011C2-8D54-4092-A15E-50B4412856F4

P921

Q52905253-E21CD750-5F1A-44E1-B881-DF48CB15C7C9

P356

A:1008344507482

P1433

Annals of Oncology

P1476

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

@en

P2093

G J Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

J B Vermorken

http://www.w3.org/2001/XMLSchema#string

J J Heimans

http://www.w3.org/2001/XMLSchema#string

M J Muller

http://www.w3.org/2001/XMLSchema#string

N K Aaronson

http://www.w3.org/2001/XMLSchema#string

T J Postma

http://www.w3.org/2001/XMLSchema#string

P304

739-744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1008344507482

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

1998-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9739440

http://www.w3.org/2001/XMLSchema#string

P921